20-Oct-2026 17:35:00
SUNPHARMA : UNLOXCYT GETS NCCN CATEGORY 2A PREFERRED DESIGNATION IN LACSCC
• NCCN elevated UNLOXCYT (cosibelimab-ipdl) to a Category 2A recommended option for locally advanced cutaneous squamous cell carcinoma (laCSCC) patients who are not candidates for curative surgery or curative radiation • Adds to the Category 2A designation in metastatic CSCC (mCSCC) assigned to UNLOXCYT in 2025 • UNLOXCYT was FDA approved in 2024 and is the first and only FDA-approved PD-L1-blocking antibody for advanced CSCC • Pivotal registration study: 55% of patients achieved objective response, including 26% complete response; at median follow-up of 24.1 months median duration of response was not reached • Fewer than 1% of patients had high-grade (Grade 3-5) immune-mediated adverse reactions; no Grade 4 or 5 imARs • NCCN Guidelines inform payer coverage policies, prior-authorization criteria, institutional formularies and clinical pathways, supporting patient access
Sun Pharmaceutical Industries Ltd
Open attachment